Key Drivers
- Strong liquidity
- Persistent losses
- High expense intensity
AIAI Summary
Personalis has moved from an R&D loss profile into an early commercial MRD pivot where Medicare/MolDX reimbursement—and the timing of physician adoption—are the binary catalysts that will determine whether its ample near‑term cash runway converts into high‑margin, recurring revenue or forces dilutive financing, so investors should prioritize coverage adjudication and execution vs. scientific validation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Persistent losses
- •High expense intensity
PSNL has ample liquidity and low leverage but is losing money and burning cash due to high OPEX/R&D and weak margins while the market prices in expected future improvement.
Price Behavior
Key Price Behavior Insights:
- •Below moving average
- •Support zone intact
- •High volatility
PSNL fell ~12% over the last month to $7.26 and trades below its last-month moving average (~$7.97), signaling short-term bearish momentum with support at $6.59–$6.72 and resistance near $7.97 and $8.90–$9.06.
High-to-low range roughly 27% over the last month, indicating material short-term volatility
Sentiment & News
Key News Insights:
- •Medicare coverage
- •Rising short interest
- •Leadership/science gains
Personalis beat Q4 loss expectations, secured Medicare coverage for breast and lung MRD tests, released supportive scientific and leadership updates, but shares fell and short interest rose.
The coverage wins and scientific validation strengthen commercial prospects, but elevated short interest and recent share weakness could pressure near-term stock performance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings